These radionuclides bind to PSMA pharmaceuticals in the form of piflufolastat 18F (18F-DCFPyL) and 68Ga-PSMA-11, demonstrating superior efficacy for prostate cancer diagnosis compared to [18F] Fluorodeoxyglucose PET (FDG-PET).6-8 Subsequently, targeted radiotherapy follows, employing either β-emitting nuclides such as 177Lu or α emitting nuclides like 225Ac attached to PSMA-617. Here, FOLH1 is linked to prostate carcinoma.